De Novo device
Eversense AP CGM System
Senseonics, Incorporated · Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA, Class II) · First FDA decision Apr 29, 2024, newest Apr 29, 2024Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
0
Naming "Eversense AP CGM"
MAUDE reports
0
Brand "Eversense AP CGM", since 2015
PubMed studies
0
Mentioning "Eversense AP CGM"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eversense AP CGM System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Eversense AP CGM SystemNew device typeDe Novo
DEN230052 · Decided Apr 29, 2024 · 264 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Eversense AP CGM", any status and sponsor, newest update first.
No registered device study names "Eversense AP CGM".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eversense AP CGM", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SBA
4,136 reports: 3,215 malfunction, 903 injury, 1 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Eversense AP CGM"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code SBA.
- Eversense 365 Continuous Glucose Monitoring (CGM) SystemSenseonics, Incorporated · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.